Nuvectis Pharma Reports Data From Its Phase 1b Trial Of NXP200 Demonstrates Objective Response Rate Based On Response Assessment In Neuro-Oncology Criteria 2.0 Of 40%; Deep Responses Were 87.5%
Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the treatment of complement-related
Nuvectis tested a new brain cancer medicine on a small group of patients. The results looked promising, so watch if larger tests confirm whether it actually works.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.